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Abstract 
 
Population aging is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to 
an estimated 2 billion people by 2050, leading to critical implications for the planning and delivery of health 
and social care.  
The most problematic expression of population aging is the clinical condition of frailty, which is a state of 
increased vulnerability that develops as a consequence of the accumulation of microscopic damages in 
many physiological systems that leads to a striking and disproportionate change in health state, even after 
an apparently small insult. 
Since little is known about the biology of frailty, an important perspective to understand this phenomenon 
is to establish how the alterations that physiologically occurs during a condition of healthy aging may 
instead promote cumulative decline with a subsequent depletion of homoeostatic reserve, and increased 
vulnerability also after minor stressor events. 
In this context, the present review aims to provide a description of the molecular mechanisms that, by 
having a critical impact on behavior and neuronal function in aging, might be relevant for the development 
of frailty. Moreover, since these biological systems are also involved in the coping strategies set in motion 
to respond to environmental challenges, we propose a role for lifestyle stress as important player to drive 
frailty in aging. 
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1. From healthy aging to frailty 
 
Life expectancy in the 20th century has greatly increased in the Western Countries. However, middle-aged 
and elderly people currently do not experience a parallel increase in health span due to the development of 
age-related pathologies. The most problematic expression of population aging is the clinical condition of 
frailty, a state of increased vulnerability to poor resolution of homoeostasis after a stressor event, which 
increases the risk of adverse outcome [1]. The high prevalence of chronic disabling conditions impact both 
on the quality of life of the individual as well as on the economic burden. On these bases it is crucial to 
understand the molecular mechanisms underlying frailty. It would be particularly important to identify the 
risk factors leading to frailty instead of healthy aging and their impact at molecular level.  
Aging is associated with structural and physiological changes in the brain, the majority of which involve the 
synapses, the most important structures in neuronal network for maintaining accurate neuronal activity 
and normal brain functions. The maintenance of synaptic functionality requires preservation of proper 
synaptic structure, coordination of synaptic vesicle release and membrane excitability, and integration of 
retrograde signals from the postsynaptic terminal [2]. During aging these processes undergo a physiological 
decline [3]and structural changes in neurons and spines as well as alterations in neurotransmitters 
receptors expression and changes in electrophysiological properties occur [4-9]. Specifically, several 
morphological changes have been reported during aging, such as reduction in synaptic density, pruning of 
the dendritic tree, loss of dendritic spines, structural changes in the presynaptic active zone and alterations 
of receptors expression and trafficking [10]. Moreover, in both in human and rodents, loss of synapses in 
aging has been associated with cognitive impairment [11-13].  
Spines represent key element of glutamatergic synapses, whose morphological and functional changes may 
affect synaptic events and excitatory synaptic signaling in aged neurons. Indeed, several lines of evidence 
indicate that aging is associated with a reduction of NMDA (N-methyl D-Aspartate) subunit expression and 
receptor activity in brain regions involved in higher brain function including synaptic plasticity, learning and 
memory [14-21].  
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Age-related changes can be detected in both excitatory and inhibitory synapses with a shift of the 
excitatory/inhibitory balance that can cause cognitive impairments [22], both in humans and in rodents[11-
13]. GABAergic transmission is markedly impaired during aging, causing an increase in cortical excitability 
[23-25]. Indeed, many studies showed a reduction of GABA (γ−aminobutirric acid) synthesis [26] probably 
due also to the downregulation of the two isoforms of the enzyme responsible of GABA synthesis, namely 
GAD65 (Glutamic Acid Decarboxylase) and GAD67 [27] in different brain areas. Furthermore also the 
composition of GABAA-B receptors changes during aging, contributing to changes in learning and memory 
processes [28]. For example, age related with an up-regulation of 1 subunits of GABAAR in the rat 
hippocampus [29]and a reduction of GABABR1 in the same brain area is associated with with spatial 
learning impairment [28, 30]. 
It is not surprising that all these alterations in turn may impact the functions of other systems playing a 
critical role in the maintenance of synaptic function, as presented in the next section. 
 
2. Molecular mechanisms altered in the aged brain 
Based on the definition of frailty, this condition may be considered the expression of a loss in resilience –
the ability to cope with adverse conditions- that may be the result of a progressive impairment in systems 
and mechanisms crucial for the proper synaptic function within the brain. Alterations of synaptic structure 
and/or function are in fact considered a potential risk factor or even a critical determinant for several 
neurodegenerative disorders associated with aging e.g. Alzheimer and Parkinson’ diseases as well as for 
cognitive decline. These pathological conditions, which are indeed characterized by reductions in synapse 
numbers and alterations of genes encoding proteins involved in synapse formation and function can be 
considered as “synaptopathies”, in which the dysfunction of the synapse is the central element [31]. 
Deficits of such systems and mechanisms would lead to increased vulnerability of the synapse to the impact 
of internal or external environment as well as to an enhanced risk to develop pathological conditions that 
characterize unhealthy aging. 
Although we are aware that multiple molecular systems may contribute to alteration of synaptic function 
during aging, in this mini-review we will specifically focus on deficits of neuronal plasticity, dysfunction of 
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hypothalamic–pituitary–adrenal (HPA) axis, alterations of immune/inflammatory system as well as 
epigenetic modifications. 
 
2.1 Deficits in neuronal plasticity and neurotrophic mechanisms 
Among the mechanism that may contribute to age-related impairment, deficits of neuronal plasticity may 
play a crucial role. This term was used for the first time by Santiago Ramon y Cajal (1852-1934) [32] and 
now refers to “the ability to make adaptive changes related to the structure and function of the nervous 
system” [33]. According to this idea, even though brain plasticity is essentially a physical process, the term 
“neuronal plasticity” can stand not only for morphological modifications – for instance of the gray matter 
that can increase or narrow [34] - or for alteration in the connections between neurons that can be formed, 
shaped, modified or impaired. Indeed, it’s important to consider that neuroplasticity is inherently 
connected and works together with the generation of new neurons (neurogenesis) and specific 
neurobiochemical changes in order to improve the brain’s ability to adapt to its environment. 
Historically, being plasticity essentially a physical and morphological phenomenon, it was thought that 
primary contributions to the decline of this brain feature were massive cell loss [35] as well as deterioration 
of dendritic branching [36]. However, we now know that the brain’s modifications occurring during normal 
and successful aging are more subtle and selective than was once believed. Indeed, the plastic changes in 
structure and function, such as modifications in the neuronal morphology and alterations in the tissue 
density, that the brain goes through do not follow a homogenous and universal pattern within the different 
brain areas but are specific and peculiar [10]. Moreover, dendritic and spine densities and dynamics and 
functional interactions among different neurotransmitters are known to change differently in specific areas 
of the brain [37]. 
Among the brain regions affected by aging, the prefrontal cortex (PFC) and the hippocampus seem to be 
particularly vulnerable, but even within and between these regions the impact of aging on neuronal 
function can differ [10]. For instance, the morphology of neurons in the PFC is more susceptible to age-
related change, as these cells show a decrease in dendritic branching in rats [38] and humans [39], while in 
the hippocampus, subregion-specific changes in the expression of genes involved in the regulation of 
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neuroplasticity have been observed [40]. Neurogenesis in the hippocampal dentate gyrus also decreases 
with age, which may contribute to the changes in brain’s plasticity over the lifespan [41]. Moreover, 
induction and maintenance of long term potentiation, alongside alterations in calcium homeostasis, 
changes with age (Lister and Barnes, 2009). These alterations could be related to oxidation of proteins that 
are involved in cellular ion homeostasis. The resulting elevated calcium concentrations can cause neuronal 
degeneration and cell death, initiating several age-related impairments such as learning and memory 
deficits [42]. 
Among all the molecular regulators of neuronal plasticity, neurotrophic factors (NTFs), and in particular the 
neurotrophin family, may be considered key players. Indeed, besides their well-established activity in 
supporting the survival, differentiation and maintenance of neuronal functions, NTFs finely modulate all the 
crucial steps of network construction, from neuronal migration to experience-dependent refinement of 
local connections [43]. It is now well-known that NTFs are important mediators of neuronal plasticity not 
only during the development of the brain but also in adulthood where they continue to support and 
modulate axonal and dendritic growth, membran  receptor trafficking, neurotransmitter release, spine 
morphogenesis and neurogenesis [44, 45]. 
The neurotrophin family comprises of NGF, Brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3) and neurotrophin-4 (NT-4) that have all evolved from a common neurotrophin ancestor gene. Their 
actions are dependent on binding to transmembrane receptor systems – the tropomyosin receptor tyrosine 
kinase family and the p75 neurotrophin receptor [46]. Neurotrophins have preferential binding for specific 
receptors: NGF binds to TrkA, BDNF and NT-4 to TrkB, and NT-3 to TrkC, although there are also a number 
of promiscuous interactions [47]. All four neurotrophins can bind to the p75 receptor and the association of 
p75 with Trk receptors can regulate the affinity of Trk receptors for each respective neurotrophin, allowing 
for greater control of ligand–receptor interactions within this system [48]. 
BDNF is a key mediator of activity-dependent processes in the brain that have a major impact on neuronal 
development and plasticity. A central function of BDNF is to help neurons to adapt, survive and to speed up 
the brain’s ability to make new connections.  
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Neurotrophic factors seem to be very much relevant in the aging brain, indeed, a negative correlation 
between BDNF serum levels and age has been reported in a large cohort of healthy elderly individuals [49]. 
In preclinical studies, the gene expression of the total form of BDNF was reduced in the hippocampus and 
in the prefrontal cortex of 18-month-old aged rats and this reduction was paralleled by a significant 
decrease in the protein levels of the neurotrophin and of its receptor TrkB [50]. Moreover, in CA1 and CA3 
sub-region of the hippocampus, aging caused reduction in total BDNF mRNA, in Exon IV-specific transcripts, 
and in transcripts with the long 3′ UTRs, an effect that may be related to the cognitive decline observed in 
these animals [51]. In line with this idea, a clinical study on a cohort of 142 participants between 59 and 81 
years of age has established a correlation between the reduction of serum BDNF levels and the shrinkage of 
the hippocampal volume with the decline in the spatial memory performance [52]. 
Interestingly, it has been shown that aging is also associated with an impaired responsiveness of BDNF 
expression and signaling to environmental stimuli [53]. For example, the abilities of challenges such as 
contextual learning [54], physical exercise [55] and brain lesion [56] to upregulate BDNF signaling are 
impaired in aged rodents.  
Supporting the involvement of BDNF in age-related variations of brain plasticity, it was shown that the 
administration of exogenous BDNF in the frontal cortex of aged rats produced a marked increase of multi-
threshold neurons of the locus coeruleus (LC), a major noradrenergic cell group with a remarkable capacity 
of remodeling, accompanied with a decrease in threshold current, suggesting that BDNF may contribute to 
functional changes in the presynaptic axon terminals of LC neurons in the aging brain [57].  
Moreover, a clinical study involving 116 adults ranged in age from 20-93 investigated the effects of BDNF 
polymorphism on multiple indices of memory (prospective, associative, subjective complaints and item). 
The results suggest that genetic predisposition to the BDNF val66met polymorphism exerts an influence on 
multiple indices of episodic memory exacerbating age-related differences in memory across the lifespan 
[58]. This polymorphism caused by a valine (Val) to methionine (Met) base change at position 66 in the 
BDNF pro-domain [59] results in a decrease of regulated BDNF secretion and is known to contribute to the 
development of psychiatric disorders such as anxiety-related behavior [60] and depressive-like behavior 
[61]. Furthermore, this polymorphism also plays a role in age-related neurodegenerative diseases, such as 
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Alzheimer’s disease and Parkinson’s disease. Specifically, decreased expression of BDNF mRNA and protein 
has been reported in the hippocampus, neocortex and Meynert nucleus basalis of patients with AD [62-64], 
while a reduced BDNF level due to decreased BDNF gene transcription has been found in the substantia 
nigra pars compacta of patients with PD [65]. 
 
2.2 HPA axis dysfunctions 
The hypothalamic–pituitary–adrenal (HPA) axis is an auto-regulating system that controls the circulating 
levels of glucocorticoids (cortisol in humans and corticosterone in rodents) (GCs). 
In physiological condition, the paraventricular nucleus of the hypothalamus secretes corticotrophin 
releasing hormone (CRH) and vasopressin (VP), which are transported to the anterior pituitary where 
adrenocorticotropic hormone (ACTH) is released. ACTH then stimulates the adrenal cortex to secrete GCs. 
The activity of the HPA axis is regulated by a negative feedback mechanism: the increased levels of GCs in 
the blood turn off their own secretion by down-regulating the release of the CRH and of ACTH. 
In the brain GCs bind two types of receptors: the mineralocorticoid (MRs) and the glucocorticoid (GRs). GRs 
are highly ubiquitous and expressed in most brain regions, whereas MRs are predominantly expressed in 
limbic regions. MR receptors have a high affinity for corticosteroids, so they are mostly occupied in basal 
conditions when circulating corticosteroid levels are low, while GRs have tenfold lower affinity and are 
more occupied as corticosteroid levels increase [66]. 
GCs can rapidly modulate neuronal activity through a non-genomic pathway (activation of membrane 
receptors that cause the release of neurotransmitters in the synaptic cleft) or a genomic pathway. In the 
latest, corticosteroid receptors translocate into the nucleus, where by binding the glucocorticoid 
responsive elements (GRE) can affect the transcriptional activity of target genes [67, 68]. 
The HPA axis exerts its effect following a U-shaped dose-response curve [69-72]. Indeed, low or high dose 
of hormone may have short term or long-term adverse consequences for the individuals, while the optimal 
response is achieved at intermediate doses. 
For example, the exposure to an acute challenge increase the release of GCs in terms of minutes to hours 
with the enhancement of synaptic transmission, LTP, learning for self-preservation, while chronic stress 
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exposure, lead to high levels of circulating GCs from months to years causing the suppression of synaptic 
functions and adaptive plasticity mechanisms leading to detrimental effect [71]. 
Several lines of clinical and preclinical evidence demonstrated that hyperactivity of the HPA axis contributes 
to neuronal and peripheral deterioration associated with aging [73-75] with a deregulation of basal HPA 
axis function and increased stress responsiveness [76]. 
In physiological conditions, cortisol is secreted over a 24-h period according to daily fluctuations [77]. In 
general, we can say that it rises early in the morning and decrease throughout the rest of the day [78] even 
if this profile may be also influenced by the wake-sleep, the light-dark cycles and the endogenous circadian 
rhythm [79]. In human, studies showing the correlation between changes in diurnal cortisol release and 
aging are variable: indeed, results are contradictory with some researcher showing a decline, others an 
increase probably due to individual’s variability [80] and methodological flaws. 
In old adults, altered morning-cortisol levels or a flatter morning-to-evening diurnal cortisol slope lead to 
HPA dysregulation and impaired neuroendocrine regulation, with increased vulnerability to stressors [78, 
80-89]. These alterations may be involved in the clinical presentation observed in frail older subjects. 
Indeed, greater diurnal cortisol secretion and smaller decline in cortisol during morning hours have been 
associated with frailty [90, 91], whereas lower diurnal cortisol is correlated with longevity [92]. These 
increases occur both in male [93] and in female [94] even if the age-related changes in cortisol appear to be 
more clear for man, as compared to woman [86, 88]. 
HPA axis alterations during aging, both in humans and in rodents, are related to modification in 
glucocorticoid circadian rhythm [81, 95], with mild increases in morning levels and a failure to increase in 
the evening [81] and with changes in GC sensitivity that could lead to an impairment of the negative 
feedback, the so-called “glucocorticoid cascade” [96]. The impaired function of the glucocorticoid negative-
feedback is associated with higher levels of circulating GCs that lead to the reduction of GR and altered GR 
signaling in the forebrain [97-101]. Dysfunction of negative feedback can produce higher stress–induced 
peaks in cortisol and prolonged stress response [102]. Moreover, aging-related elevation of glucocorticoids 
levels appears to threaten hippocampal neurons and may contribute to the loss of dendrite complexity in 
the rat hippocampus [103]. 
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Aging is also associated with alteration of CRH and VP that may in turn account for the aberrant activity of 
the HPA axis. While some studies show progressive decreases of CRH expression [104, 105], the majority of 
the studies found increases of CRH production with advancing age [75, 83, 106-108]. Moreover, increased 
CRH levels during aging can be detrimental and may contribute to the development of age-related 
pathologies, such as depression, anxiety, neurodegeneration, immune and metabolic disorders[109].On the 
contrary, VP increases in parvocellular neurons during aging, while a decrease has been shown to occur in 
the suprachiasmatic nucleus [75]. 
Furthermore, the 11- beta hydroxyl steroid dehydrogenases (11βHSD-1), the enzyme responsible of 
restoring active GCs is significantly increased in the hippocampus of aged mice, thus amplifying the steroid 
action and contributing to the aging process [110, 111]. 
GR down-regulation in hippocampus leads to memory impairment and HPA axis dysregulation, as well as 
deficits in the activation of GR-dependent transcription [99, 101, 112, 113]. Moreover, plasma 
glucocorticoids levels correlate with deficits in spatial learning and hippocampal degeneration in aged rats 
[114, 115] and with dysfunction of hippocampus-dependent memory tasks and reduced hippocampal 
volume in aged humans [82], while high salivary cortisol concentration predict declining performance on 
declarative memory tests [116]. Despite this, many older individuals have cognitive performance similar to 
younger ones [97, 117-120] and this can be due to the accumulation of a lifetime of experience that could 
alter the progression of brain aging, a phenomenon named “allostatic load” [121, 122]. 
 
2.3 Alterations of Immune/inflammatory 
Another system altered in aging is the immune/inflammatory system. Historically, the brain was believed to 
be an immunologically privileged space, functioning fully isolated from the immune system. However, it is 
now accepted that there is a wide and constant bi-directional communication between the immune system 
and the CNS, across the relatively impenetrable blood- brain barrier (BBB) [123, 124]. As a consequence of 
this connection, neural activity is dramatically affected during and following an immune challenge that 
occurs in the periphery [125, 126], leading to the production of cytokine -signaling molecules possessing 
unique immunomodulatory functions- within the brain tissue, with activated microglia -resident immune 
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cells of the CNS- driving the response [127]. Moreover, the discovery of the meningeal lymphatic system’s 
capability of carrying fluids, immune cells, and macromolecules from the CNS to the draining lymph nodes 
[128, 129]corroborates the relevance of the signaling between the brain and the peripheral immune 
system.  
As we age, our immune system undergoes several modifications of the inflammatory status with a decline 
of the adaptive immunity, called immunosenescence, coupled with a concomitant activation of the innate 
immune system, so-called “inflamm-aging”, which may lead to a low-grade, chronic, systemic inflammation 
[130-132]. Immunosenescence of the acquired system has received a great attention in recent years. After 
birth, thymic productivity decreases with age, resulting in reduced T-cell repertoire in parallel with an 
increased growth of memory and effector-memory cells [133]. This imbalance culminates in a reduced 
ability to clear novel pathogens, prolonging infection duration as well as an increase in functionally distinct 
T-cell populations, which have an amplified pro-inflammatory phenotype [134]. Increases in numbers of 
antigen-specific cells with age are associated with an increment in the number of terminally differentiated 
‘senescent’ cells, which occupy a large proportion of immune space. These cells, particularly CD8
+
, are 
extremely potent producers of inflammatory cytokines and cultures of senescent CD8
+ 
T cells show 
resistance to apoptosis, permanent loss of CD28 expression, altered cytokine profiles, reduced ability to 
respond to stress and various functional changes [135]. Moreover, with age these antigen-specific cells do 
not proliferate properly and after mitogenic/viral stimulation produce more IL-6 and TNF than their 
younger counterparts [136]. Therefore, T-cell immunosenescence is characterized by an increased 
proinflammatory phenotype and most probably contributes to inflamm-aging in a manner dependent on 
previous exposure to antigenic challenges and exhaustion of T-cell repertoire [137].  
Inflamm-aging is thought to be a result of a cumulative lifetime exposure to antigenic stimuli caused by 
infections as well as exposure to non-infective antigens [138]. The consequent immune response, tissue 
injury and production of reactive oxygen species (ROS) that cause oxidative damage also triggers the 
release of additional cytokines, primarily from cells of the innate immune system [139]. This results in a 
vicious cycle, where the release of cytokines provokes a further damage, immune activation and 
remodeling of the tissue.  
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Within the innate immune system, microglia, as part of the myelomonocytic lineage, constitute the 
predominant cells and serve many functions including immune-surveillance of the microenvironment for 
pathogen invasion, danger signals, cellular debris, apoptotic cells, and alterations in neuronal phenotype 
[140]. In the young adult brain, normally quiescent microglia become activated in response to a threat 
[141] and undergo morphological changes, proliferation and production of pro-inflammatory cytokines 
[140]. Once the threat is resolved, alternatively activated microglia produce anti-inflammatory cytokines in 
addition to other signaling molecules that facilitate a return to resting state [141]. For example, 
alternatively activated microglial cells secrete growth factors such as BDNF, which promotes the growth, 
survival, differentiation of neurons and synapse formation[142]. In contrast, during normal aging, microglia 
undergo a process of senescence. Senescent microglia, which has been detected in aged rodents, exhibit 
telomere shortening when cultured [143], dissimilar brain distribution and decreased motility and 
phagocytic activity [144, 145], smaller dendritic arbors that look more variable in size, less circularly 
symmetric, and more elongated in shape [146, 147]. Moreover, histo-pathological evidences of aged 
human brains depict an increase in microglia expr ssion of IL-1β and CD11b [148] and increased mRNA 
levels of IL-1β were found in microglia of aged mice following inflammatory lipopolysaccharide stimulation, 
suggesting that an exaggerated inflammatory response occurs in healthy aging [149].  
These age-related abnormalities in structure, ramification and therefore function are called “microglia 
dystrophy” and are indicative of a senescent phenotype [150]. Recently, Bisht et al. coined the name “dark 
microglia” to identify a new cells phenotype rarely present in the adult brain, marked by condensation of 
cytoplasm and nucleoplasm, accompanied by endoplasmic reticulum dilation -the most well-characterized 
sign of oxidative stress- engulfed dendritic spines and axon terminals and nuclear chromatin remodeling 
[151, 152]. This phenotype becomes abundant not only during pathologic state, such as chronic stress or 
neurodegenerative diseases, but it was also observed during normal aging [151].  
In summary, even during healthy aging individuals show a progressive increase in neuroinflammation 
characterized by increased glial activation and elevated steady-state levels of inflammatory cytokines. This 
altered inflammatory status may contribute to the cognitive decline typical of elderly people as well as to 
other pathological conditions as well as to a state of enhanced vulnerability. 
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2.4. Epigenetic modifications 
During aging, insults or damages that normally accumulate with age (oxidation, advanced age glycation 
products, DNA damage, amyloid accumulation etc.) can interfere with normal epigenetic control. 
Epigenetics refers to the heritable but reversible modifications on DNA that regulate the transcription of 
genes. These processes are modulated, throughout the lifespan, by environmental cues that can be 
“remembered” due to changes in the epigenome [153]. Epigenetic mechanisms include histone 
modifications, DNA methylationand microRNA (miRNA). 
Recently, it has been shown that DNA methylation represents a critical biomarker for aging that may 
predict the age of human cell type and tissue [154-157]. In particular, DNA methylation status is close to 
zero in embryonic and iPS and also reflects cell passage number, supporting a strict link between epigenetic 
and aging process [154]. Moreover, DNA methylation pattern is significantly different between 
centenarians and newborn [157], with a more homogeneous profile in the latest. In particular, centenarians 
show loss of DNA methylation in promoters poor of CpG, while hypermethylation was observed in CpG 
island promoters [157]. 
Age-associated methylation occurs in a site and tissue-specific manner, with specific hypermethylation for 
example in human colon or liver [158, 159]. 
Furthermore, age is also associated with altered expression of DNMT1 and DNMT3, two key enzymes 
involved in DNA methylation, with a decreased expression of DNMT1 [160-162] and an increase in DNMT3 
expression [160].Regarding histone modifications, the changesin histone methylation and acetylation 
observed during aging [163] is associated with an unbalance between histone acetyltransferases (HATs) 
and histone deacetylase (HDACs) with an increase in HDACs, negative regulators of memory acquisition and 
maintenance [164]. Accordingly, sirtuins (SIRT), which regulates histone acetylation, affect the aging 
process. For example, in yeast Sir2 regulates longevity and its abundance decline with aging [165]and SIRT-
6 deficient mice have premature aging traits [166]. DNA methylation and histone modifications are strictly 
related since age-related hypomethylated regions are associated with various histone modifications, 
including H3K27ac, H3K4m1, H3K4m2, H3K4m3 and H3K9ac [167]. 
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Taking together these results suggest that the lasting changes in DNA methylation may represent a form of 
molecular memory, even if it is currently unclear if age-associated changes in epigenetic pattern are merely 
an epiphenomenon or play a casual role in the development of age-related disease. 
 
3. Role of stressful events 
As previously described, alterations of different mechanisms contributing to synaptic function may occur 
during normal aging. However, when and how the impairment of these mechanisms leads to frailty and its 
pathological consequences is still unknown. We propose that, beside the physiological alteration of these 
molecular mechanisms, a critical impact on the switch from healthy aging to a pathological state may 
derive from the inability to cope with stressful and challenging events. 
It is well known that stress represents a critical risk factor for the development of several pathologies, 
including those associated with aging. However, another important issue to consider is that the stress 
impact may have a different grade of severity with respect to the time in which this experience takes place. 
Accordingly, we can speculate that while the stress response in young, healthy individuals is adaptive, 
without a health burden, if such stimuli occur in old age or in unhealthy subjects, the outcome may be 
different, resulting in a number of alterations that might favor the insurgence of a pathological condition.  
In line with this idea, we have previously demonstrated that the expression and function of the 
neurotrophin BDNF are reduced in animals exposed to chronic stress at different stages of life, an effect 
that is associated with pathological phenotype [168-171]. Since BDNF plays a critical role in resilience and a 
reduction of its expression is important for stress-coping strategies [172], the changes observed in aged 
rats may impair resilience thus contributing to functional deficits associated with aging.  
Moreover, it is known that the HPA axis is the primary stress system in the body and it is sensitive to both 
acute and chronic stresses thus influencing aging process [173], an effect probably mediated by 
glucocorticoids circulating levels [174]. During aging, acute stress can prolong physiological recovery with a 
higher peak in cortisol in humans [175], but in rodents a contradictory effects were reported with 
corticosterone response reduced, exaggerated or prolonged in old compared to young rats [81]. On the 
contrary, chronic stress exposure impaired HPA sensitivity, probably by reducing GR concentration in 
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hippocampus and hypothalamus [98] thus leading to less functional feedback and high levels of GCs 
circulating [176, 177]. Nevertheless, many older adults exhibit resilience to the HPA axis dysregulation 
[178], by compensating and adapting to the physiological deficits that accompany aging. 
In elderly humans, the higher cortisol level is also associated with increase cognitive decline [116, 173, 179, 
180]. Accordingly, a critical risk factor for the poor cognitive function associated with aging is life-long 
exposure to stressful events [71, 181] and both sustained GC basal levels and stress can drive hippocampal 
neuron loss and associated cognitive decline [182]. Moreover, environmental factors seem to contribute to 
age associated changes in DNA methylation [154, 183-185].  
Indeed, cumulative lifetime stress correlates with accelerated aging brain in humans [186]. In addition, a 
high number of the genes interested by changed in methylations during aging contain a functional 
glucocorticoid responsive elements supporting the possibility that stress-induced acceleration of epigenetic 
aging is mediated by glucocorticoid signaling [186, 187].  
Aging may also affect the inflammatory response to stress exposure. Indeed, the overall increase of pro-
inflammatory mediators and the general activation of microglia observed after an adverse stimuli, are 
exacerbated when the adverse event occur in old age[188, 189]. For example, it has been reported that the 
activation of peripheral innate immune system induced by lipopolysaccaride injection in 24-month old aged 
mice results in an exaggerated neuroinflammatory response, with a significant up-regulation of the cerebral 
expression of the pro-inflammatory cytokines IL-1β and IL-6, as compared to 3-6 month old mice [190]. 
Interestingly, these changes were associated with behavioral alterations and with a more severe sickness 
behavior syndrome in aged mice [190]. A similar result was found in aged mice following a peripheral 
immune-challenge with E. coli, where the inflammatory response was not only exacerbated but also 
prolonged [191]. In addition, it has been demonstrated an over-reactivity of aged microglia when exposed 
ex-vivo to lipopolysaccharide[192] as well as in vivo after an experimental injury [193], thus leading to 
extended chronic inflammation. 
All in all, these observations clearly indicate that the response to stress exposure is affected during aging, 
which may lead to an exacerbated cellular and functional response that may contribute to the switch from 
healthy to frailty aging (Fig.1). 
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4. Conclusions 
There is no doubt that everyone experiences adverse events during life that impact both health and quality 
of life. However, trajectories of health in aging can vary significantly depending on the individual. 
According to our hypothesis, a reduction of resilience may underlie an increased risk to develop pathologic 
conditions during aging. In line with this idea, an elder fragility would be the consequence of reduced 
function and responsiveness of biological systems crucial for coping with stressful events.  
It is therefore fundamental to identify and characterize the mechanisms that may contribute to the 
resilience or the vulnerability to stressful events, since such mechanisms may be significantly altered in the 
aged brain. However, a major gap in this field of research is that the studies are limited to assess molecular 
alterations under basal or resting conditions, without information on if and how these functional 
impairments result in lack of stress responsiveness. 
The investigation of these mechanisms will be critical to identify genes and pathways whose changes may 
contribute to achieve a better understanding of the risk architecture for age-related vulnerability and may 
represent potential targets for the development of novel pharmacological intervention. 
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Legend 
Figure 1: Normal brain aging is characterized by alterations of neuroplasticity, epigenetic mechanisms, 
neuroinflammation and HPA axis function. Stress by acting on the same systems, may drive the switch 
between health and frailty. 
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